Actinic Keratosis Treatment Global Market Report 2024

The global actinic keratosis treatment market has grown strongly in recent years. It will grow from $3 billion in 2023 to $3.24 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The historical growth in actinic keratosis treatment can be attributed to factors such as increased treatment adherence, market competition dynamics, initiatives focused on patient education, advancements in dermatological practices, and ongoing research and participation in clinical trials. These factors collectively contributed to the progression and development of treatments for actinic keratoses during the historical period.

The global actinic keratosis treatment market is expected to see strong growth in the next few years. It will grow to $4.36 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The anticipated growth in the forecast period for actinic keratosis treatment can be attributed to factors such as heightened patient education and engagement, the integration of digital health solutions, increasing awareness about the condition, a focus on preventive dermatology, and the evolving trends toward personalized medicine. Major trends expected in the forecast period include a shift towards combination therapies, ongoing technological advancements, the adoption of personalized treatment approaches, a rise in incidence rates, and a preference for minimally invasive treatments within the field of actinic keratosis management.

The escalating prevalence of actinic keratosis is anticipated to drive the growth trajectory of the market for actinic keratosis treatment. Actinic keratosis, a consequence of prolonged sun exposure, manifests as rough, scaly skin patches and necessitates treatment to mitigate precancerous lesions. The surge in actinic keratosis cases underscores the amplified demand for treatment options, driving pharmaceutical research and advocating the use of topical treatments. According to the World Cancer Research Fund International's February 2022 report, the incidence of actinic keratosis surged from over 150,000 new cases in 2020 to 197,700 cases in 2022, emphasizing the pivotal role of treatment advancements in addressing this condition.

The expanding demographic of elderly individuals is poised to be a significant catalyst propelling the growth trajectory of the actinic keratosis treatment market. Addressing the needs of the geriatric populace - typically aged 65 and older - remains pivotal due to their susceptibility to actinic keratosis, attributed to prolonged sun exposure and skin aging. Actinic keratosis treatment interventions are crucial in curbing precancerous skin lesions, consequently reducing the risk of skin cancer among this demographic. As per the World Health Organization's projection in October 2022, the population aged 60 and above is estimated to surge from 1 billion in 2020 to 1.4 billion by 2030, with a subsequent doubling to 2.1 billion by 2050. This demographic shift underscores the necessity for focused treatments catering to the geriatric population susceptible to actinic keratosis.

Innovations in product offerings emerge as a defining trend shaping the landscape of the actinic keratosis treatment market. Leading industry players are keenly introducing pioneering products to fortify their market presence in the domain of actinic keratosis treatments. For instance, in July 2021, Almirall, a US-based pharmaceutical firm, secured approval for Klisyri (tirbanibulin), a topical microtubule inhibitor heralding a groundbreaking approach to actinic keratosis treatment. This innovative topical treatment represents a first-in-class microtubule inhibitor strategically designed for adult use, specifically for application on the face or scalp, demonstrating a selective antiproliferative mechanism of action to address actinic keratosis.

Key industry players in the actinic keratosis treatment market are rolling out medical products aimed at preventing actinic keratosis and non-melanoma skin cancer. For instance, in February 2021, Eucerin, a renowned skincare brand based in Germany, introduced Actinic Control SPF100. This dermatological product is specifically formulated to avert actinic keratosis while offering robust sun protection. Actinic Control SPF100 represents a pioneering medical solution that not only shields against sun-induced skin damage but also serves as a preventive measure against actinic keratosis and non-melanoma skin cancer. It caters to individuals with compromised skin and acts as an adjunctive treatment for those afflicted by actinic keratosis.

In March 2022, Coegin Pharma, a Sweden-based company at the forefront of a phase I/II trial featuring their lead candidate AVX001 targeting actinic keratosis and actively engaged in the preclinical development of AVX420 for conditions like leukemia and chronic kidney disease, executed a merger with Follicum. This strategic alliance aimed to reinforce Coegin Pharma's drug development portfolio by placing a significant emphasis on tackling diabetes complications. Follicum, a biotech company based in Sweden, brings complementary expertise and resources to Coegin Pharma, fortifying its position in drug development and enhancing its focus on addressing various medical conditions.

Major companies operating in the actinic keratosis treatment market report are Sun Pharmaceutical Industries Ltd., Novartis AG, Hill Dermaceuticals Inc., Bausch Health Companies Inc., LEO Pharma A/S, Almirall SA, Biofrontera AG, Galderma SA, Mylan NV, Cipher Pharmaceuticals Inc., Pierre Fabre Pharmaceuticals Inc., Tolmar Pharmaceuticals Inc., Stanford Chemicals Company, Glaxo Smith Kline PLC, Alma Lasers Ltd., 3M Company, Nestle SA, Cutanea Life Sciences Inc., DUSA Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., G&W Laboratories Inc., Hikma Pharmaceuticals PLC, Innocutis Holdings LLC, Mayne Pharma Group Limited, Meda AB, Merz Pharma GmbH & Co KGaA, Perrigo Company PLC, PharmaDerm A division of Fougera Pharmaceuticals Inc., Promius Pharma LLC, Ranbaxy Laboratories Limited, Sandoz International GmbH, Stiefel Laboratories Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Zydus Pharmaceuticals Inc., Dermira Inc., Menlo Therapeutics Inc., Sol-Gel Technologies Ltd., Verrica Pharmaceuticals Inc.

North America was the largest region in the actinic keratosis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the actinic keratosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of actinic keratosis treatment include topical applications, procedural interventions, photodynamic therapy, and other modalities. Topical treatment involves the application of specific medications like fluorouracil cream, imiquimod cream, ingenol mebutate gel, and diclofenac gel. These medications are utilized across various healthcare settings, including hospitals, private dermatology clinics, laser therapy centers, cancer treatment facilities, spas, rejuvenation centers, and in homecare practices.

This report provides actinic keratosis treatment market statistics, including actinic keratosis treatment industry global market size, regional shares, competitors with an actinic keratosis treatment market share, detailed actinic keratosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the actinic keratosis treatment industry. This actinic keratosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The actinic keratoses treatment market includes revenues earned by entities by providing cryotherapy, laser therapy, chemical peels, and medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.